PW Medtech (01358) has announced the interim results for the first half of 2026 for its subsidiary, Sichuan Ruijian Medical. The subsidiary recorded revenue of RMB 309 million, reflecting a year-on-year increase of 3.62%.
Net profit attributable to shareholders of Sichuan Ruijian Medical reached RMB 78.905 million, marking an 8.2% growth compared to the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.